HDAC9 and neoplasm: A number of studies have suggested that hydroxamate-based compounds might inhibit HDAC activity to cause cell death and suppress in vivo tumor growth (Rajak et al., 2014; West and Johnstone, 2014; Chuang et al., 2017).